Home›Drug Pipeline› Tripterygium glycosides provide renal protective effects in animal models of diabetic nephropathy
Tripterygium glycosides provide renal protective effects in animal models of diabetic nephropathyTripterygium glycosides show potential to protect kidneys in diabetes
Frontiers in MedicinePublished September 14, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that tripterygium glycosides show renal protection in animal models but require strict dosing to avoid toxicity.
This meta-analysis synthesizes data from 1,481 animals to evaluate the renal protective effects and mechanisms of tripterygium glycosides (TGs) in models of diabetic nephropathy. The analysis found that TGs significantly reduced several markers, including Scr, BUN, 24h UP, 24h UA, 24h UMA, KW, KI, BG, TC, TG, MGA, and MGV. Additionally, ALB levels increased, while ALT, AST, WBC, RBC, and PLT levels showed no significant change.
Markers related to oxidative stress, inflammation, renal fibrosis, podocyte injury, and autophagy were modulated by the intervention. However, the authors note that the methodological quality was moderate to low, and the overall evidence quality was moderate to very low. These limitations suggest that the findings should be interpreted with caution.
From a clinical perspective, TGs demonstrated a favorable renal protective effect in animal models. However, the authors caution that specific dosing and duration are critical; doses exceeding 9 mg/kg/day or treatment durations exceeding 8 weeks were associated with hepatotoxicity and hematological toxicity. A dose of 6 to 9 mg/kg/day for up to 8 weeks was identified as a balance between efficacy and safety in these models. Clinical translation to human patients is not supported by this data.
How this fits prior evidence
This meta-analysis of animal models addresses a gap in understanding the pharmacological effects of tripterygium glycosides on renal function. While other findings have explored botanical interventions like Euonymus alatus for glucose metabolism and Vitamin D for urinary markers, this study specifically evaluates TGs. It provides a preclinical basis for the renal protective effects of TGs, though it does not confirm or contrast the specific genetic markers or miR-based biomarkers previously identified in human populations.
Living with diabetes often means facing a serious risk: kidney damage, known as diabetic nephropathy. Researchers looked at how a compound called tripterygium glycosides (TGs) affects kidney health in animal models. They found that TGs significantly reduced several markers of kidney damage and improved certain indicators of kidney function.
While the results are promising for protecting the kidneys, the study also highlighted important safety boundaries. High doses or long treatment periods caused issues with liver enzymes and white blood cell counts. To stay safe, the researchers suggested that specific doses and shorter treatment times are necessary to avoid these side effects.
It is important to remember that this research was done in animals, not humans. The quality of the evidence is currently considered moderate to low. Because of these limitations, we cannot yet know how this treatment would work in people or if it is a safe clinical option.
What this means for you:
Tripterygium glycosides may protect kidneys in diabetic models, but high doses can cause liver and blood issues.
Common questions
What did the study find about kidney protection?
The study found that tripterygium glycosides significantly reduced several markers of kidney damage, such as Scr and BUN. It also showed that the treatment helped improve certain indicators of kidney function in the animal models tested.
Are there any side effects to this treatment?
Yes, high doses over 9 mg/kg/day caused elevated liver enzymes (AST) and lower white blood cell counts. Additionally, treating for more than 8 weeks increased liver enzymes (ALT). Lower doses between 6 and 9 mg/kg/day were found to be safer.
Can this be used to treat humans with diabetes?
This study was conducted on animal models, not humans. Because the evidence quality is moderate to low and the study was preclinical, it is not yet known if this treatment is safe or effective for people.
BackgroundDiabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus (DM), clinically characterized by progressive loss of renal function and/or persistent albuminuria. Tripterygium glycosides (TGs) have been used in the clinical treatment of DN. There are many animal experiments on TGs intervention in DN, but the evidence from these studies remains unclear.ObjectiveThis study aims to summarize the renal protective effects and mechanisms of TGs in DN animal models.MethodsA comprehensive search of animal studies from the inception of 8 databases to May 2026 was conducted. The bias risk of the included studies was evaluated using SYRCLE’s risk of bias tool. The evidence certainty of the outcomes was assessed using the GRADE method. The meta-analysis was conducted using RevMan 5.4 and Stata 17.0 software.ResultsA total of 55 studies involving 1,481 animals were included. Analysis showed that TGs significantly reduced Scr, BUN, 24h UP, 24h UA, 24h UMA, KW, KI, BG, TC, TG, MGA, and MGV levels while increasing ALB levels, but did not significantly affect ALT, AST, WBC, RBC, or PLT levels. Additionally, TGs modulated the expression of most markers related to oxidative stress, inflammation, renal fibrosis, podocyte injury, and autophagy. Subgroup analysis by intervention time suggested that longer intervention time (>8 weeks) increased ALT levels. Dose-effect-toxicity analysis indicated that medium doses (6–9 mg/kg/day) balanced efficacy and safety, while high doses (>9 mg/kg/day) elevated AST levels and reduced WBC levels. The methodological quality was moderate to low, and the evidence quality was moderate to very low.ConclusionTGs have a favorable renal protective effect on DN animals, which can improve renal function, basic indicators, glucose and lipid metabolism, and renal tissue pathological changes. For safety reasons, the intervention time (≤8 weeks) and dose (6–9 mg/kg/day) should be strictly restricted to prevent potential hepatotoxicity and hematological toxicity. Its protective mechanisms mainly include anti-oxidative stress, relieving inflammation, inhibiting renal fibrosis, alleviating podocyte injury, and regulating autophagy. Given the limited methodological and evidential quality of existing studies, more high-quality studies are needed to validate this conclusion.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/, Identifier CRD420251251933.
